Exhibit 99.1
American Oriental Bioengineering Reports Third Quarter 2007
Financial Results
— Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 —
— 3Q07 Net Income Increased 58% Compared to 3Q06 to $11.9 Million, or $0.16 per Diluted Share —
— Company Provides Financial Outlook for 2007 and 2008 —
New York, November 5, 2007 — American Oriental Bioengineering, Inc. (NYSE: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the third quarter of 2007.
Revenue for the third quarter of 2007 increased 60.7% to $43.5 million from $27.1 million in the third quarter of 2006. Revenue from PBP products increased 78.4% to $35.5 million from $19.9 million in the prior year’s third quarter, driven primarily by the Jinji products series, including the Company’s Yi Mu Cao product, and by strong revenue growth from prescription products, including Shuanghuanlian and the Cease Enuresis Gel. Within the PBP product category, prescription product revenue increased 43.7% to $15.6 million compared to $10.9 million in the prior year period. OTC product revenue increased 120.4% to $19.8 million from $9.0 million in the prior year period. Revenue from PBN products increased 11.7% to $8.0 million from $7.2 million in the third quarter of 2006, due to increased demand for the Company’s soy peptide series of products.
Gross profit in the third quarter of 2007 increased 73.3% to $30.7 million from $17.7 million in the third quarter of 2006. Gross profit margin increased 510 basis points to 70.5% from 65.4% in the prior year’s period. The increase in gross profit was a result of increased sales of OTC products, which carry higher margins, and improved operating efficiencies across all business segments.
Operating expenses in the third quarter increased 100% to $16.7 million compared to $8.3 million in the prior year period. This increase was a result of additional investment related to the Jinji product promotional efforts, as well as increased marketing and advertising expenses related to the Company’s efforts to increase market awareness of its brands and products and higher selling expenses to support the Company’s growth. Operating income for the third quarter increased 49.5% to $14.0 million from $9.4 million in the third quarter of 2006. Operating margin was down slightly to 32.1%, from 34.5% in the prior year’s third quarter, due to additional investment in the business, including a larger salesforce and higher advertising budget.
Net Income for the third quarter of 2007 increased 58.2% to $11.9 million, or $0.16 per diluted share, compared to $7.6 million, or $0.12 per diluted share, in the prior year period.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering commented, “Our overall results for the third quarter demonstrate the achievement made through the execution of our two pronged strategy, which is to expand our business performance through organic growth and acquisitions. We expect this strategy will continue to bring us further opportunities down the road. We have completed two acquisitions recently that have improved our product line and broadened our distribution reach. During the third quarter, we closed on the Changchun Xinan Pharmaceutical Group (CCXA) acquisition, and after the close of the third quarter we completed the acquisition of Guangxi Boke Pharmaceutical Company (Boke). Similar to our other acquisitions, we see the potential to expand CCXA’s and Boke’s sales, improve margins and enhance the operating infrastructure of each company.”
Financial Expectations
For the full year 2007, the Company anticipates revenue of approximately $160.0 million, a 45.2% increase compared to prior year revenue of $110.2 million. This guidance includes approximately $8.0 million in revenue from CCXA and Boke. For the full year, the Company anticipates diluted earnings per share of approximately $0.60, based on an estimated weighted average diluted share count of 72.0 million for the full year. This guidance does not account for any other potential acquisitions for the remainder of 2007.
For the full year 2008, the Company expects continued seasonal quarter-to-quarter fluctuations, as well as short-term integration costs. Nonetheless, the Company anticipates a sustainable organic revenue growth rate of at least 30%, which includes all product lines managed by AOB for at least four quarters.
“We have laid the foundation for future growth and we are pleased with the traction we are seeing with our latest acquisitions as well as in the organic growth driven by our existing products. Our growing and diversified product portfolio, far reaching distribution network and extensive, highly skilled marketing team serves as a competitive advantage for our business that will continue to establish AOBO as a leading cultivator and consolidator of plant-based medicine products well into the future,” concluded Liu.
The Company will conduct a conference call to discuss the third quarter 2007 results today, Monday, November 5, 2007 after the market close at 4:30 pm ET. Listeners may access the call by dialing 1-913-312-0857. A webcast will also be available on Company’s website at www.bioaobo.com. A replay of the call will be available through November 12, 2007. Listeners may access the replay by dialing 1-719-457-0820, password 4449446.
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a leading, fully integrated, plant based pharmaceutical and plant based nutraceutical company dedicated to improving health through the development, manufacture and commercialization of modernized plant based products in China. For more information, visit http://www.bioaobo.com.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact Information:
Wilfred Chow
SVP Finance
212-786-7568
Bill Zima & Ashley Ammon MacFarlane
Integrated Corporate Relations, Inc.
203-682-8200
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
| SEPTEMBER 30, 2007 | DECEMBER 31, 2006 | |||||
| UNAUDITED | ||||||
CURRENT ASSETS | ||||||
Cash and cash equivalents | $ | 170,624,005 | $ | 87,784,419 | ||
Accounts receivable, net of reserve of $285,007 and $39,776 at September 30, 2007 and December 31, 2006, respectively | 15,333,892 | 11,141,057 | ||||
Inventories, net of $615,050 and $615,552 provision for slow moving inventories at September 30, 2007 and December 31, 2006, respectively | 15,349,597 | 10,684,316 | ||||
Advances to suppliers | 2,580,911 | 1,950,101 | ||||
Notes receivable | 2,223,683 | 3,238,161 | ||||
Other receivables | 89,630 | 37,545 | ||||
Due from employees | 190,849 | 585,050 | ||||
Deposit for acquisition | 4,420,770 | — | ||||
Deferred consulting expenses | 97,500 | 166,600 | ||||
Total Current Assets | 210,910,837 | 115,587,249 | ||||
LONG-TERM ASSETS | ||||||
Plant and equipment, net | 42,596,023 | 32,194,957 | ||||
Land use rights, net | 40,539,275 | 32,937,743 | ||||
Construction in progress | 173,073 | 326,121 | ||||
Deferred tax assets | 1,600,940 | 1,797,153 | ||||
Other intangible assets, net | 9,976,982 | 383,755 | ||||
Goodwill | 11,467,270 | 1,933,100 | ||||
Long-term investment and advance | 190,882 | 113,868 | ||||
Total Long-Term Assets | 106,544,445 | 69,686,697 | ||||
| �� | ||||||
TOTAL ASSETS | $ | 317,455,282 | $ | 185,273,946 | ||
See accompanying notes to the condensed consolidated financial statements
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
LIABILITIES AND SHAREHOLDERS’ EQUITY
| SEPTEMBER 30, 2007 | DECEMBER 31, 2006 | |||||
| UNAUDITED | ||||||
CURRENT LIABILITIES | ||||||
Accounts payable | $ | 4,781,481 | $ | 2,871,981 | ||
Other payables and accrued expenses | 7,443,882 | 4,549,867 | ||||
Taxes payable | 2,243,868 | 2,211,542 | ||||
Short-term bank loans | 6,119,007 | 8,314,679 | ||||
Current portion of long-term bank loans | 977,739 | 1,450,905 | ||||
Customer deposits | 1,393,819 | 2,263,654 | ||||
Notes payable | 69,125 | 66,216 | ||||
Payable for acquisition | 11,681,890 | — | ||||
Other liabilities | 769,721 | 1,606,334 | ||||
Total Current Liabilities | 35,480,532 | 23,335,178 | ||||
LONG-TERM LIABILITIES | ||||||
Long-term bank loans, net of current portion | 2,601,679 | 915,909 | ||||
Long-term notes payable | 274,424 | 255,836 | ||||
Deferred tax liabilities | 8,882,761 | 4,580,698 | ||||
Other liabilities | 1,597 | 9,083 | ||||
Total Long-Term Liabilities | 11,760,461 | 5,761,526 | ||||
TOTAL LIABILITIES | 47,240,993 | 29,096,704 | ||||
COMMITMENTS | ||||||
SHAREHOLDERS’ EQUITY | ||||||
Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at September 30, 2007 and December 31, 2006, respectively | 1,000 | 1,000 | ||||
Common stock, $0.001 par value; 150,000,000 shares authorized; 74,909,301 and 64,230,369 shares issued and outstanding, respectively | 74,909 | 64,230 | ||||
Stock to be issued | 197,083 | 599,069 | ||||
Additional paid-in capital | 172,963,877 | 92,307,960 | ||||
Retained earnings (the restricted portion of retained earnings is $8,498,766 at September 30, 2007 and December 31, 2006, respectively) | 86,853,096 | 58,826,911 | ||||
Accumulated other comprehensive income | 10,124,324 | 4,378,072 | ||||
Total Shareholders’ Equity | 270,214,289 | 156,177,242 | ||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 317,455,282 | $ | 185,273,946 | ||
See accompanying notes to the condensed consolidated financial statements
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND
COMPREHENSIVE INCOME (UNAUDITED)
| THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
REVENUES | $ | 43,514,049 | $ | 27,075,059 | $ | 103,062,573 | $ | 69,238,089 | ||||||||
COST OF GOODS SOLD | 12,833,252 | 9,373,245 | 31,048,916 | 24,292,034 | ||||||||||||
GROSS PROFIT | 30,680,797 | 17,701,814 | 72,013,657 | 44,946,055 | ||||||||||||
Selling and marketing | 5,644,776 | 2,230,490 | 12,210,509 | 5,896,617 | ||||||||||||
Advertising | 6,934,160 | 3,607,212 | 16,150,754 | 8,844,564 | ||||||||||||
General and administrative | 3,742,364 | 2,223,335 | 9,234,426 | 6,781,231 | ||||||||||||
Depreciation and amortization | 377,856 | 288,070 | 1,054,128 | 654,890 | ||||||||||||
Total operating expenses | 16,699,156 | 8,349,107 | 38,649,817 | 22,177,302 | ||||||||||||
INCOME FROM OPERATIONS | 13,981,641 | 9,352,707 | 33,363,840 | 22,768,753 | ||||||||||||
INTEREST INCOME, NET | 360,365 | 106,804 | 375,604 | 550,057 | ||||||||||||
OTHER INCOME (EXPENSE), NET | (12,191 | ) | 6,379 | 133,284 | 15,540 | |||||||||||
INCOME BEFORE INCOME TAXES | 14,329,815 | 9,465,890 | 33,872,728 | 23,334,350 | ||||||||||||
INCOME TAXES | 2,386,189 | 1,915,266 | 5,846,543 | 4,922,419 | ||||||||||||
NET INCOME | 11,943,626 | 7,550,624 | 28,026,185 | 18,411,931 | ||||||||||||
OTHER COMPREHENSIVE INCOME | ||||||||||||||||
Foreign currency translation gain | 2,344,696 | 949,154 | 5,746,252 | 1,587,449 | ||||||||||||
Income tax expense related to other comprehensive income | (351,704 | ) | (142,373 | ) | (861,938 | ) | (238,117 | ) | ||||||||
TOTAL OTHER COMPREHENSIVE INCOME, NET OF TAX | 1,992,992 | 806,781 | 4,884,314 | 1,349,332 | ||||||||||||
COMPREHENSIVE INCOME | $ | 13,936,618 | $ | 8,357,405 | $ | 32,910,499 | $ | 19,761,263 | ||||||||
NET INCOME PER SHARE | ||||||||||||||||
BASIC | $ | 0.16 | $ | 0.12 | $ | 0.41 | $ | 0.30 | ||||||||
DILUTED | $ | 0.16 | $ | 0.12 | $ | 0.40 | $ | 0.30 | ||||||||
WEIGHTED AVERAGE SHARES OUTSTANDING | ||||||||||||||||
BASIC | 74,379,650 | 62,704,918 | 68,012,018 | 62,200,836 | ||||||||||||
DILUTED | 75,331,015 | 62,849,767 | 69,234,193 | 62,328,290 | ||||||||||||
See accompanying notes to the condensed consolidated financial statements